<DOC>
	<DOCNO>NCT01354418</DOCNO>
	<brief_summary>This study assess food-effect bioavailability extend release formulation phenylephrine HCl bioequivalence market immediate release phenylephrine HCl product .</brief_summary>
	<brief_title>Bioequivalence Single Dose Phenylephrine Extended Release Tablets Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours ( P08340 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>In good health Female participant must pregnant Agrees use two acceptable method birth control throughout study Agrees take monoamine oxidase inhibitor ( MAOI ) 2 week prior , , 2 week end study Any significant medical condition contraindication use phenylephrine HCl , might interfere study , require treatment expect affect blood pressure Any infectious disease within 4 week prior initial treatment administration History malignancy , except basal cell carcinoma Can comply requirement abstain use drug ( except acetaminophen herbal/vitamin supplement ) within 14 day prior study alcohol xanthinecontaining substance ( coffee , chocolate ) within 72 hour prior study Received investigational drug within thirty day prior study drug dose Known apparent current former drug addict alcoholic Positive Human Immunodeficiency Virus ( HIV ) antibody , hepatitis B surface antigen , hepatitis C antibody Can accept highfat , highcalorie breakfast Known allergy intolerance phenylephrine HCl Have use phenylephrinecontaining product within 2 week prior study start Have smoke tobacco , use tobacco product , use nicotinecontaining smoke cessation aid within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>